pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
AMGEN · news · pharmadog
← back to AMGEN
News mentioning AMGEN
112
stories
Jul 16, 26
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
fiercebiotech
Jul 13, 26
Building a workforce engine for biomanufacturing
fiercebiotech
Jul 9, 26
UK price watchdog recommends against Amgen's Lumakras in lung cancer
endpoints
Jul 8, 26
STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
stat
Jul 7, 26
STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
stat
Jul 6, 26
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
stat
Jul 2, 26
STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals
stat
Jul 2, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Jul 2, 26
Court halts Colorado price cap on Amgen's blockbuster Enbrel
endpoints
Jul 2, 26
Roche KRAS drug succeeds in head-to-head lung cancer study
biopharma dive
Jul 2, 26
STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
stat
Jul 2, 26
STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug
stat
Jul 2, 26
Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study
endpoints
Jul 1, 26
92Bio revives a T cell engager it had transferred to Amgen
endpoints
Jun 30, 26
Viridian may have edge over Amgen in eye drug showdown, analysts argue
biopharma dive
Jun 29, 26
NEJM retracts pivotal data for Amgen's Tavneos
endpoints
Jun 29, 26
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 26, 26
On second try, Acadia drug gets nod from European regulators
biopharma dive
Jun 18, 26
What’s next for GLP-1 weight loss drugs?
stat
Jun 17, 26
A new Westlake-backed biotech takes aim at migraines
biopharma dive
Jun 12, 26
Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
endpoints
Jun 12, 26
STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and more
stat
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
Jun 10, 26
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
biopharma dive
Jun 8, 26
Tango data add to growing momentum for pancreatic cancer drugs
biopharma dive
Jun 5, 26
Study data convince Lundbeck to push new migraine drug forward
biopharma dive
Jun 4, 26
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
stat
May 29, 26
Bristol Myers unveils data for one of its next-gen blood cancer drugs
biopharma dive
May 18, 26
Amgen stands by rare disease drug Tavneos amid Japan liver toxicity report
endpoints
← prev
page 3 of 4
next →
